Yusuke Chihara Selected Research

Yusuke Chihara Research Topics

Disease

47	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2024 - 01/2018
26	Neoplasms (Cancer) 03/2024 - 12/2018
10	Lung Neoplasms (Lung Cancer) 04/2024 - 01/2019
4	COVID-19 04/2023 - 01/2022
3	Disease Progression 01/2024 - 10/2018
3	Adenocarcinoma of Lung 04/2023 - 01/2020
3	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2023 - 11/2019
2	Pneumonia (Pneumonitis) 04/2024 - 01/2022
2	Neoplasm Metastasis (Metastasis) 11/2023 - 03/2019
2	Cachexia 09/2023 - 01/2021
2	Carcinoma (Carcinomatosis) 01/2023 - 01/2020
2	Pericardial Effusion 12/2022 - 01/2019
1	Inflammation (Inflammations) 09/2023
1	Bacteremia 04/2023
1	Vasculitis (Vasculitides) 01/2023
1	Brain Neoplasms (Brain Tumor) 01/2023
1	Weight Loss (Weight Reduction) 01/2022
1	Severe Acute Respiratory Syndrome 01/2022
1	Prostatic Neoplasms (Prostate Cancer) 08/2021
1	Body Weight (Weight, Body) 01/2020
1	Sarcopenia 04/2019
1	Starvation 03/2019
1	Acidosis 03/2019
1	Hypoxia (Hypoxemia) 03/2019
1	Constipation 01/2019

Drug/Important Bio-Agent (IBA)

18	ErbB Receptors (EGF Receptor)IBA 04/2024 - 01/2018
16	Tyrosine Kinase InhibitorsIBA 04/2024 - 01/2018
16	Immune Checkpoint InhibitorsIBA 01/2024 - 01/2019
13	osimertinibIBA 04/2024 - 01/2019
8	Docetaxel (Taxotere)FDA Link 03/2024 - 01/2019
8	B7-H1 AntigenIBA 10/2023 - 08/2019
6	PlatinumIBA 01/2024 - 01/2018
5	RamucirumabIBA 03/2024 - 08/2019
5	pembrolizumabIBA 11/2023 - 08/2019
3	AntibodiesIBA 03/2024 - 11/2019
3	LigandsIBA 11/2023 - 01/2022
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2019 - 01/2019
2	durvalumabIBA 09/2023 - 01/2020
2	Etoposide (VP 16)FDA LinkGeneric 04/2023 - 01/2023
2	RNA (Ribonucleic Acid)IBA 02/2023 - 01/2022
2	Bevacizumab (Avastin)FDA Link 12/2022 - 01/2019
2	amrubicinIBA 09/2022 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2018
2	NivolumabIBA 05/2020 - 08/2019
2	AfatinibIBA 02/2019 - 10/2018
2	Cytotoxins (Cytolysins)IBA 01/2019 - 01/2019
1	serum P-component (CIt)IBA 10/2023
1	C-Reactive ProteinIBA 09/2023
1	Epidermal Growth Factor (EGF)IBA 06/2023
1	Anti-Infective Agents (Microbicides)IBA 04/2023
1	SteroidsIBA 04/2023
1	Phosphotransferases (Kinase)IBA 02/2023
1	Proteins (Proteins, Gene)FDA Link 02/2023
1	Proton Pump InhibitorsIBA 01/2023
1	pegfilgrastim (Neulasta)FDA Link 01/2023
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2023
1	EnzymesIBA 09/2022
1	DNA (Deoxyribonucleic Acid)IBA 09/2022
1	Topoisomerase II InhibitorsIBA 09/2022
1	mRNA VaccinesIBA 01/2022
1	4- (3'- (2'- chlorophenyl)- 2'- propen- 1'- ylidene)- 1- phenyl- 3,5- pyrazolidinedioneIBA 01/2022
1	Immunoglobulin G (IgG)IBA 01/2022
1	Interferon Type IIBA 01/2022
1	Dihydrotachysterol (AT 10)IBA 01/2022
1	alectinibIBA 11/2021
1	Anaplastic Lymphoma KinaseIBA 11/2021
1	Prednisolone (Predate)FDA LinkGeneric 08/2021
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021
1	Antinuclear AntibodiesIBA 11/2020
1	atezolizumabIBA 10/2020
1	Histone Deacetylase InhibitorsIBA 01/2020
1	Mirtazapine (Rexer)FDA LinkGeneric 01/2020
1	Antineoplastic Agents (Antineoplastics)IBA 01/2020
1	Phosphopyruvate Hydratase (Enolase)IBA 11/2019
1	dacomitinibIBA 08/2019
1	Therapeutic UsesIBA 08/2019
1	Indicators and Reagents (Reagents)IBA 04/2019
1	Glucose (Dextrose)FDA LinkGeneric 03/2019
1	Angiogenesis InhibitorsIBA 03/2019
1	Nicotine FDA Link 02/2019
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 02/2019
1	LaxativesIBA 01/2019
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2019
1	Vinorelbine (Navelbine)FDA LinkGeneric 01/2019
1	Pemetrexed (MTA)FDA Link 01/2019
1	Gefitinib (Iressa)FDA Link 10/2018

Therapy/Procedure

28	Therapeutics 04/2024 - 01/2019
17	Drug Therapy (Chemotherapy) 01/2024 - 01/2018
9	Immunotherapy 10/2023 - 01/2019
2	Chemoradiotherapy 09/2023 - 01/2020
1	Induction Chemotherapy 09/2022
1	Combination Drug Therapy (Combination Chemotherapy) 01/2021
1	Aftercare (After-Treatment) 06/2020
1	Radiotherapy 01/2020